Over the last 12 months, MapLight Therapeutics insiders reported 2 buys totaling $15.5M and 7 sales totaling $11.5M across SEC Form 4 filings. 44% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 22,082 | $12.54 | $277K | -9.8% | plan |
| Jul 30, 2026 | Catalyst4, Inc.10% | ▲ Buy | 1,209,225 | $12.66 | $15.3M | +6.1% | 4 tranches · indirect |
| Jul 28, 2026 | Cox TroyD | ▲ Buy | 15,620 | $9.52 | $149K | — | indirect |
| Jul 17, 2026 | Foff Erin PennockChief Medical Officer · O | ▼ Sale | 47,158 | $36.78 | $1.7M | -13.6% | plan · 9 tranches |
| Jul 17, 2026 | Hanson KristopherGeneral Counsel · O | ▼ Sale | 16,508 | $36.82 | $608K | -10.2% | 7 tranches |
| Jul 17, 2026 | GILLIS JONATHANCAO and Interim CFO · O | ▼ Sale | 36,979 | $37.12 | $1.4M | -20.4% | plan · 7 tranches |
| Jul 17, 2026 | Kreitzer AnatolChief Discovery Officer · O | ▼ Sale | 36,284 | $37.09 | $1.3M | -17.2% | plan · 7 tranches |
| Jul 17, 2026 | Kroeger Christopher A.Chief Executive Officer · O·D | ▼ Sale | 147,639 | $36.87 | $5.4M | -10.6% | 7 tranches |
| Jul 17, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 18,267 | $36.88 | $674K | -7.5% | 7 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MPLT feed.